Compare SCWO & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | SCWO | MOLN |
|---|---|---|
| Founded | 2021 | 2004 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Environmental Services | |
| Sector | Utilities | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.8M | 157.8M |
| IPO Year | N/A | 2021 |
| Metric | SCWO | MOLN |
|---|---|---|
| Price | $0.24 | $4.39 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.75 |
| AVG Volume (30 Days) | ★ 1.2M | 3.4K |
| Earning Date | 11-12-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,910,340.00 | N/A |
| Revenue This Year | $5,945.19 | N/A |
| Revenue Next Year | $106.82 | $1,000.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 508.52 | N/A |
| 52 Week Low | $0.16 | $3.36 |
| 52 Week High | $1.09 | $5.91 |
| Indicator | SCWO | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 42.52 | 55.40 |
| Support Level | $0.21 | $3.98 |
| Resistance Level | $0.30 | $4.40 |
| Average True Range (ATR) | 0.03 | 0.18 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 46.95 | 68.12 |
374Water Inc offers a technology that transforms wet wastes such as sewage sludge, biosolids, food waste, hazardous and non-hazardous waste, and forever chemicals (e.g., PFAS) into recoverable resources by focusing on waste as a valuable resource for water, energy, and minerals. The company's business activities include manufacturing processes and waste recycling and treatment processes, which currently involve the use, treatment, storage, transfer, handling and/or disposal of hazardous materials, chemicals and wastes.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.